PGFC
BVS icon

Peapack-Gladstone Financial Corp’s Bioventus BVS Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,500
Closed -$56K – 702
2022
Q4 		$56K Buy
+21,500
New +$93.9K ﹤0.01% 664

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Peapack-Gladstone Financial Corp's BVS Position: Q1 2023 in Review

Peapack-Gladstone Financial Corp sold out of Bioventus (BVS) in Q1 2023, closing a stake of 21,500 shares — an estimated $56K sold.

Peapack-Gladstone Financial Corp first reported a position in BVS in Q4 2022 and held it in 1 quarter. The position peaked at $56K in Q4 2022. 71 funds tracked by Wall St. Rank hold BVS as of Q1 2023.

  • Peapack-Gladstone Financial Corp reported no remaining Bioventus position as of Q1 2023 after selling out during the quarter.
  • Peapack-Gladstone Financial Corp sold 21,500 Bioventus shares in Q1 2023, an estimated $56K.
  • Peapack-Gladstone Financial Corp first reported a position in Bioventus in Q4 2022 and held it in 1 quarter.
  • Peapack-Gladstone Financial Corp's Bioventus position peaked at $56K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Bioventus as of Q1 2023.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2023, filed 15 May 2023.